Japanese regenerative medicine trailblazer Instinct Brothers Co. Ltd. announced Tuesday that it will go public via a merger with special purpose acquisition company Relativity Acquisition Corp., in a blockbuster $242 million deal crafted by three top law firms.
Once the transaction is finalized, Instinct Brothers will operate as a wholly owned subsidiary of Relativity, rebranding as Instinct Bio Technical Co. Inc. and trading on the Nasdaq under the ticker symbol BIOT, according to a statement.
The deal sees Darryl Edward & Co. advising Instinct Brothers, while Loeb & Loeb LLP and Barnett & Linn LLP provide legal counsel to the SPAC entity.
Accelerating the Future of Regenerative Medicine
Instinct Brothers has pioneered an advanced model for stem cell-based regenerative therapies, targeting longevity, immune system enhancement, and innovative disease prevention strategies. The company’s ecosystem blends stem cell-based cosmeceuticals, cutting-edge R&D, university collaborations, proprietary manufacturing, and clinical applications in regenerative medicine.
